BLCO
Bausch & Lomb Corp Health Care Ophthalmic Goods Russell 3000
$20.00Close
$7.1BMarket cap
$14.56 – $20.4052-week range
Late-januaryNext report · estimated
Highlights
Strengths
- Near its high 2% below its 52-week high
Cautions
- Trend not confirmed 7 of 8 conditions · 150-day under the 200-day
- Extended 4.2 ATR above its 50-day average
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
2%
1wk
up 14.5%
price change
1mo
up 17.6%
price change
12-month return
up 32%
market up 11% ·
its own up 18%
F-score
—
— Not assessed
Altman Z
0.95
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.1×
price / book
Earnings yield
up 1.0%
EBIT / enterprise value
Cheaper than
47%
of the market · around average
Revenue growth
up 6%
year on year
EPS growth
—
latest quarter
Sales growth
up 7%
latest quarter · -2 pts
ROE
down 6%
return on equity
Free cash margin
down 1%
-$66.0M FCF
D/E
0.78
long-term debt / equity
Net debt / EBITDA
8.7×
Interest cover
0.3×EBIT / interest
Trade setup
ATR%
3.6%
$0.72 a day · 2×ATR $18.56
RS
79 / 99
vs the universe
Trend
7 / 8
150-day under the 200-day
Relative volume
2.4×
vs 50-day average
Up/down volume
1.32
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- 150-day average above the 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Operating profit does not cover interest Earnings before interest cover the interest bill 0.3 times. Below 0.5× the debt is being serviced from something other than operations.
- Heavily indebted Net debt is 8.7 times EBITDA — roughly 9 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported
Oct 28, 2026
Results reaction
Oct 28, 2026+16% vs market2 sessions after results
Financials
- Net -7%
- Free cash -1%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.8B | $3.8B | $4.1B | $4.8B | $5.1B |
| Operating income | $260.0M | $329.0M | $207.0M | $130.0M | $162.0M | $113.0M |
| Net income | -$18.0M | $182.0M | $6.0M | -$260.0M | -$317.0M | -$360.0M |
| Net margin | -1% | 5% | 0% | -6% | -7% | -7% |
| Earnings per share | -$0.05 | $0.52 | $0.02 | -$0.74 | -$0.90 | -$1.02 |
| Free cash flow | $269.0M | $680.0M | $170.0M | -$198.0M | -$59.0M | -$66.0M |
| Free cash margin | 8% | 18% | 5% | -5% | -1% | -1% |
| Cash | $238.0M | $174.0M | $354.0M | $331.0M | $305.0M | $383.0M |
| Long-term debt | — | $0 | $2.4B | $4.5B | $4.7B | $5.0B |
| Shareholders' equity | $10.0B | $9.3B | $7.0B | $6.8B | $6.5B | $6.4B |
| Shares outstanding | — | 350m | 350m | 350.91m | 352.40m | 354.21m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 28, 2026 | Quarterly ↗ | Sep 30, 2026 | 28d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| Apr 29, 2026 | Quarterly ↗ | Mar 31, 2026 | 29d |
| Feb 18, 2026 | Annual ↗ | Dec 31, 2025 | 49d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Jul 30, 2025 | Quarterly ↗ | Jun 30, 2025 | 30d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 19, 2025 | Annual ↗ | Dec 31, 2024 | 50d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results ↗ |
| Oct 28, 2026 | Director or officer change ↗ |
| Oct 13, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 6, 2026 | Material agreement · Director or officer change · Other events ↗ |
| Jul 29, 2026 | Results ↗ |
| May 20, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Feb 18, 2026 | Results ↗ |
| Jan 2, 2026 | Material agreement · New obligation · Other events ↗ |
| Dec 17, 2025 | Director or officer change ↗ |
| Dec 12, 2025 | Other events ↗ |
| Nov 13, 2025 | Regulation FD ↗ |